Together with ONWARD Medical Co-Founders, Bryan, Garnier & Co hosted an exclusive Brain-Computer Interface (BCI) event on Thursday, 24 April 2025, at our Paris headquarters.
The event brought together a select group of institutional investors for a roundtable discussion with ONWARD Medical’s co-founders, Prof. Grégoire Courtine, Neuroscientist, Co-Founder and Scientific Advisor at ONWARD Medical and Dr. Jocelyne Bloch, Neurosurgeon, Co-Founder and Medical Advisor at ONWARD Medical, to explore the transition from neuroscience research to entrepreneurship, with a deep dive into the emerging frontier of neurotechnology: BCI.
The session opened with remarks from Bryan, Garnier & Co highlighting the fast-evolving BCI space, its nascent commercial landscape, and the transformative potential for healthcare. This was followed by a candid and forward-looking conversation with ONWARD Medical’s founders, who shared their journey, their vision, and the groundbreaking developments behind their ARC-BCI platform — a therapeutic system designed to restore movement by bridging the brain directly to the spinal cord.
ARC-BCI is set to be a revolutionary therapeutic device, whose secret sauce — as commented by the speakers — lies in the development of a brainGPT, aimed at empowering ARC-IM’s therapeutic potential by bridging to human thoughts.
ONWARD Medical (Euronext: ONWD; US OTCQX ONWRY) is a medical technology company creating therapies to restore movement, function, and independence in people with spinal cord injury (SCI) and movement disabilities. Building on more than a decade of science and preclinical research conducted at leading neuroscience laboratories, the Company has received ten Breakthrough Device Designations from the US Food and Drug Administration for its ARC Therapy™ platform.
Get in touch with our analyst to access the full recording.
Maria Vara
About Bryan, Garnier & Co
Bryan, Garnier & Co is a European growth investment bank that helps healthcare and technology companies become global champions. By combining extensive sector expertise with an entrepreneurial mindset, Bryan Garnier provides companies and their investors with independent growth strategic advice, and privileged access to buyers and capital in Europe, the US and Asia.
As a full-service investment bank, the firm offering includes private and public growth financing solutions, mergers and acquisitions (M&A) advisory, research insights, and institutional sales & execution. Founded in 1996, Bryan Garnier & Co is an independent partnership with around 200 employees located in major financial centres in Europe and the US.